Cargando…

Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis

BACKGROUND AND AIM: Current observational studies have compared the effectiveness and safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still disputed. This meta-analysis was conducted to compare the effect of edoxaban in patients with AF. METHODS: We perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Bailin, Cheng, Winglam, Kaisaier, Wulamiding, Gu, Zhenbang, Zhu, Wengen, Jiang, Qiuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665752/ https://www.ncbi.nlm.nih.gov/pubmed/38027839 http://dx.doi.org/10.1016/j.heliyon.2023.e21740

Ejemplares similares

Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis
por: Wulamiding, Kaisaier, et al.
Publicado: (2022)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
por: Diaz, Alejandro Bimbo, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

Editorial: Effects of oral anticoagulant therapy in atrial fibrillation patients with comorbidities
por: Li, Runkai, et al.
Publicado: (2023)

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
por: Acharya, Tushar, et al.
Publicado: (2015)

Preventing stroke in atrial fibrillation patients – clinical utility of oral anticoagulants
por: Jhawar, Manish B, et al.
Publicado: (2012)

Protocol for LASER: A Randomized Evaluation and an Associated Registry of Early Anticoagulation With Edoxaban After Ischemic Stroke in Patients With Atrial Fibrillation
por: Alrohimi, Anas, et al.
Publicado: (2021)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
por: Liu, Xuyang, et al.
Publicado: (2022)

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
por: Chang, Ting-Yung, et al.
Publicado: (2018)

Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation
por: Galea, Roberto, et al.
Publicado: (2023)

Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
por: Schäfer, Andreas, et al.
Publicado: (2020)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient
por: Yates, Scott W
Publicado: (2013)

Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants
por: Morais, João, et al.
Publicado: (2016)

Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014)

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
por: Bisson, Arnaud, et al.
Publicado: (2017)

Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Stroke prevention within primary care: management of atrial fibrillation using oral anticoagulation
por: Lotufo, Paulo Andrade
Publicado: (2018)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2021)

Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
por: Tiili, Paula, et al.
Publicado: (2021)

Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation
por: Polymeris, Alexandros A., et al.
Publicado: (2021)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation
por: Ment, Jerome
Publicado: (2015)

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities
por: Dobesh, Paul P., et al.
Publicado: (2015)

Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation
por: Medlinskiene, Kristina, et al.
Publicado: (2021)

A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
por: Stambler, Bruce S
Publicado: (2013)

Periprocedural, short-term, and long-term outcomes following transcatheter tricuspid valve repair: a systemic review and meta-analysis
por: Wu, Zexuan, et al.
Publicado: (2023)

Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation
por: Seiffge, David J., et al.
Publicado: (2020)

Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke
por: Eun, Mi-Yeon, et al.
Publicado: (2021)

Oral Anticoagulation Timing in Patients with Acute Ischemic Stroke and Atrial Fibrillation
por: Chang, Po-Yin, et al.
Publicado: (2021)

Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation
por: Carlisle, Matthew A., et al.
Publicado: (2022)

Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014)

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study
por: Hohmann, Christopher, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_154octcdj9ehahgr3rtmlchkl7